ZOITECHLAB Competitors

Join us at SynergyLabs® in our pursuit of innovation! As a concept-to-shelf American manufacturer, we produce over 150 branded and private-label products sold in pet specialty, veterinary, grocery, mass merchandisers, and big-box stores across 65 countries worldwide. Our chemistry and research and development experts lead the way in scientific and innovative products for dogs and cats, including nutritional supplements, grooming, health, and veterinary items. For 6 consecutive years, Inc 5000 has recognized SynergyLabs as one of America's Fastest-Growing Privately Held Companies. Our dedication to growing healthy, active, and happy pets (and their parents!) is at the heart of everything we do. Join us in our mission to innovate and improve the lives of pets worldwide.

Ziontech is a trusted, security focused, end to end systems integrator; implementing strategic and flexible solution, customized to customer’s need with a wide enterprise security portfolio, supporting emerging trends as cloud, mobility, BYOD and collaborative business for organization that enables the right individuals to access the right resources at the right times for the right reasons. It helps customers optimize Database Security & identity and access management practices, stop advanced threats, protect critical assets, safeguard the cloud and mobile and use security as a competitive advantage. In addition ZionTech offers a best of breed cloud based application product portfolio designed ground-up to address needs of the modern day extended enterprise that enables enterprise mobility with social and analytic capabilities and helps to deliver the experience customers expect and the performance the market demands with increased business opportunities and faster innovations. The Information Exchange Cloud Platform from ZionTech helps business achieve superior digital experience for consumers through mobile enabling them to expand market and revenue streams using multiple channels and allows them to connect employees and partners to enterprise data anywhere, anytime.

APEX is a patient-driven pharmaceutical company focused on optimizing the standard of mental health care with psilocybin by bringing data supported, clinically evaluated drugs to market for depression and anxiety in PTSD. Our strategy is focused on developing pharmaceutical products through a phased clinical program evaluating safety and efficacy across multiple indications, alongside a robust early access program. APEX has two GMP Certified drug assets. APEX-52 is microdose synthetic psilocybin for clinical evaluation, currently in active phase 2b trials, and APEX-25 is the company’s macro dose drug asset, developed for in-clinic dosing with assisted psychotherapy. APEX recently launched North America’s first take-home psilocybin trial, and received approval for the world’s largest psilocybin clinical trial to-date both evaluating APEX-52 in the treatment of anxiety and depression in diagnosed PTSD. APEX is driven by an experienced and passionate leadership team from the Veteran community, healthcare, drug policy and emerging sectors who want to make a difference and disrupt the $380+ billion global mental health market. Find out more at apexlabs.com